Buffalo Biolabs, LLC (BBL) announced today that it has been awarded a phase I Small Business Technology Transfer (STTR) grant. This is a second STTR grant won by BBL. The new grant supports the work conducted by the company and its collaborators in the field of preclinical oncology. Dr. Katerina Gurova, a researcher at Roswell Park Cancer Insitute and a co-Investigator for the grant commented: “We are pleased to have received the support from Small Business Administration. The funds will be instrumental to advance our research of pathways affecting pancreatic cancer”.
The federal STTR program expands funding opportunities in federal innovation research and development by supporting public/private sector partnerships to include joint venture opportunities for small businesses and nonprofit research institutions.
Buffalo Biolabs, LLC (BBL), founded in 2009 by Dr. Andrei V. Gudkov, PhD, DSci, is a Buffalo, NY based Contract Research Organization (CRO) focused on preclinical services and drug discovery, primarily in the fields of oncology, immunology and wound care. BBL operates from its headquarters in Buffalo Niagara Medical Campus.